Key result
A percutaneous left ventricular assist device successfully treated cardiogenic shock in a patient with acute pancreatitis-induced takotsubo cardiomyopathy, improving left ventricular ejection fraction.
Case Report (n=1)
No
Percutaneous left ventricular assist devices can be successfully used as a bridge to recovery in patients with severe cardiogenic shock secondary to acute pancreatitis-induced takotsubo cardiomyopathy.
May support LVAD bridging in pancreatitis-induced takotsubo shock; hypothesis-generating single case leaves broader use open.
A 63-year-old man was admitted for severe acute pancreatitis. On day 3 of hospitalisation, he developed shortness of breath and acute pulmonary oedema. Echocardiogram revealed global hypokinesis with a left ventricular ejection fraction of 20%, and he was diagnosed with takotsubo cardiomyopathy. He developed cardiogenic shock which was treated successfully with a percutaneous left ventricular assist device. His left ventricular ejection fraction improved by hospital follow-up 3 weeks later.
No takes yet. Share an insight, caveat, or question.
Koop et al. (2018) conducted a case report in Acute pancreatitis-induced takotsubo cardiomyopathy and cardiogenic shock (n=1). Percutaneous left ventricular assist device (Impella 2.5) was evaluated on Clinical recovery and left ventricular ejection fraction improvement. A percutaneous left ventricular assist device successfully treated cardiogenic shock in a patient with acute pancreatitis-induced takotsubo cardiomyopathy, improving left ventricular ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: